NCT06118203

Brief Summary

Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 2, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 4, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 5, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 11, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 7, 2023

Completed
Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

1.2 years

First QC Date

September 11, 2023

Last Update Submit

March 24, 2026

Conditions

Pulmonary Embolism

Outcome Measures

Primary Outcomes (1)

  • Endothelial biomarker measurement

    Change in plasma CD147 level between baseline and 4 weeks

    4 weeks

Secondary Outcomes (1)

  • Plasma proteomics

    4 weeks

Study Arms (2)

Open label Semaglutide

Patients presenting with acute intermediate - high risk PE consenting to participation in drug arm of study

Drug: Semaglutide

Control

Patients presenting with acute intermediate - high risk PE consenting to participation in control arm of study

Interventions

SemaglutideDRUG

Semaglutide in addition to standard of care

Also known as: None applicable
Open label Semaglutide

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Acute admission with acute pulmonary embolism

You may qualify if:

  • Acute pulmonary embolism

You may not qualify if:

  • Concurrent use of GLP-1 agonist

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Colm McCabe

London, SW3 6NP, United Kingdom

Location

Related Publications (1)

  • Samaranayake CB, Chen YC, Fang M, Rhodes CJ, Song S, Sabrin F, Ashek A, Bonnici K, Mukherjee B, Howard LS, Pinguel J, Rawal B, Semple T, Price LC, Wort SJ, Rudd T, Zhao L, McCabe C. GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling. Eur Heart J Open. 2025 Dec 24;6(1):oeaf170. doi: 10.1093/ehjopen/oeaf170. eCollection 2026 Jan.

    PMID: 41536961DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

Patient plasma samples, collected at baseline and at study completion 4 week time-point

MeSH Terms

Conditions

Pulmonary Embolism

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesEmbolismEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Colm McCabe, MD

    Imperial College London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2023

First Posted

November 7, 2023

Study Start

January 2, 2022

Primary Completion

March 4, 2023

Study Completion

March 5, 2023

Last Updated

March 27, 2026

Record last verified: 2026-03

Locations

GB(1)